Human apolipoprotein E4 alters the amyloid-β 40: 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model

John D. Fryer, Kelly Simmons, Maia Parsadanian, Kelly R. Bales, Steven M. Paul, Patrick M. Sullivan, David M. Holtzman

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is characterized by the aggregation and deposition of the normally soluble amyloid-β (Aβ) peptide in the extracellular spaces of the brain as parenchymal plaques and in the walls of cerebral vessels as cerebral amyloid angiopathy (CAA). CAA is a common cause of brain hemorrhage and is found in most patients with AD. As in AD, the ε4 allele of the apolipoprotein E (apoE) gene (APOE) is a risk factor for CAA. To determine the effect of human apoE on CAA in vivo, we bred human APOE3 and APOE4 "knock-in" mice to a transgenic mouse model (Tg2576) that develops amyloid plaques as well as CAA. The expression of both human apoE isoforms resulted in a delay in Aβ deposition of several months relative to murine apoE. Tg2576 mice expressing the more fibrillogenic murine apoE develop parenchymal amyloid plaques and CAA by 9 months of age. At 15 months of age, the expression of human apoE4 led to substantial CAA with very few parenchymal plaques, whereas the expression of human apoE3 resulted in almost no CAA or parenchymal plaques. Additionally, young apoE4-expressing mice had an elevated ratio of Aβ 40:42 in brain extracellular pools and a lower 40:42 ratio in CSF, suggesting that apoE4 results in altered clearance and transport of Aβ species within different brain compartments. These findings demonstrate that, once Aβ fibrillogenesis occurs, apoE4 favors the formation of CAA over parenchymal plaques and suggest that molecules or treatments that increase the ratio of Aβ 40:42 may favor the formation of CAA versus parenchymal plaques.

Original languageEnglish (US)
Pages (from-to)2803-2810
Number of pages8
JournalJournal of Neuroscience
Volume25
Issue number11
DOIs
StatePublished - Mar 16 2005
Externally publishedYes

Fingerprint

Cerebral Amyloid Angiopathy
Apolipoprotein E4
Amyloid beta-Protein Precursor
Amyloid
Apolipoproteins E
Amyloid Plaques
Alzheimer Disease
Brain
Apolipoprotein E3
Intracranial Hemorrhages
Extracellular Space
Transgenic Mice
Protein Isoforms
Alleles

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Apolipoprotein E
  • Cerebral amyloid angiopathy
  • Ratio
  • Transgenic models

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Human apolipoprotein E4 alters the amyloid-β 40 : 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. / Fryer, John D.; Simmons, Kelly; Parsadanian, Maia; Bales, Kelly R.; Paul, Steven M.; Sullivan, Patrick M.; Holtzman, David M.

In: Journal of Neuroscience, Vol. 25, No. 11, 16.03.2005, p. 2803-2810.

Research output: Contribution to journalArticle

Fryer, John D. ; Simmons, Kelly ; Parsadanian, Maia ; Bales, Kelly R. ; Paul, Steven M. ; Sullivan, Patrick M. ; Holtzman, David M. / Human apolipoprotein E4 alters the amyloid-β 40 : 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. In: Journal of Neuroscience. 2005 ; Vol. 25, No. 11. pp. 2803-2810.
@article{e70dace4178541589774b8b66b568fc7,
title = "Human apolipoprotein E4 alters the amyloid-β 40: 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model",
abstract = "Alzheimer's disease (AD) is characterized by the aggregation and deposition of the normally soluble amyloid-β (Aβ) peptide in the extracellular spaces of the brain as parenchymal plaques and in the walls of cerebral vessels as cerebral amyloid angiopathy (CAA). CAA is a common cause of brain hemorrhage and is found in most patients with AD. As in AD, the ε4 allele of the apolipoprotein E (apoE) gene (APOE) is a risk factor for CAA. To determine the effect of human apoE on CAA in vivo, we bred human APOE3 and APOE4 {"}knock-in{"} mice to a transgenic mouse model (Tg2576) that develops amyloid plaques as well as CAA. The expression of both human apoE isoforms resulted in a delay in Aβ deposition of several months relative to murine apoE. Tg2576 mice expressing the more fibrillogenic murine apoE develop parenchymal amyloid plaques and CAA by 9 months of age. At 15 months of age, the expression of human apoE4 led to substantial CAA with very few parenchymal plaques, whereas the expression of human apoE3 resulted in almost no CAA or parenchymal plaques. Additionally, young apoE4-expressing mice had an elevated ratio of Aβ 40:42 in brain extracellular pools and a lower 40:42 ratio in CSF, suggesting that apoE4 results in altered clearance and transport of Aβ species within different brain compartments. These findings demonstrate that, once Aβ fibrillogenesis occurs, apoE4 favors the formation of CAA over parenchymal plaques and suggest that molecules or treatments that increase the ratio of Aβ 40:42 may favor the formation of CAA versus parenchymal plaques.",
keywords = "Alzheimer's disease, Amyloid-β, Apolipoprotein E, Cerebral amyloid angiopathy, Ratio, Transgenic models",
author = "Fryer, {John D.} and Kelly Simmons and Maia Parsadanian and Bales, {Kelly R.} and Paul, {Steven M.} and Sullivan, {Patrick M.} and Holtzman, {David M.}",
year = "2005",
month = "3",
day = "16",
doi = "10.1523/JNEUROSCI.5170-04.2005",
language = "English (US)",
volume = "25",
pages = "2803--2810",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "11",

}

TY - JOUR

T1 - Human apolipoprotein E4 alters the amyloid-β 40

T2 - 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model

AU - Fryer, John D.

AU - Simmons, Kelly

AU - Parsadanian, Maia

AU - Bales, Kelly R.

AU - Paul, Steven M.

AU - Sullivan, Patrick M.

AU - Holtzman, David M.

PY - 2005/3/16

Y1 - 2005/3/16

N2 - Alzheimer's disease (AD) is characterized by the aggregation and deposition of the normally soluble amyloid-β (Aβ) peptide in the extracellular spaces of the brain as parenchymal plaques and in the walls of cerebral vessels as cerebral amyloid angiopathy (CAA). CAA is a common cause of brain hemorrhage and is found in most patients with AD. As in AD, the ε4 allele of the apolipoprotein E (apoE) gene (APOE) is a risk factor for CAA. To determine the effect of human apoE on CAA in vivo, we bred human APOE3 and APOE4 "knock-in" mice to a transgenic mouse model (Tg2576) that develops amyloid plaques as well as CAA. The expression of both human apoE isoforms resulted in a delay in Aβ deposition of several months relative to murine apoE. Tg2576 mice expressing the more fibrillogenic murine apoE develop parenchymal amyloid plaques and CAA by 9 months of age. At 15 months of age, the expression of human apoE4 led to substantial CAA with very few parenchymal plaques, whereas the expression of human apoE3 resulted in almost no CAA or parenchymal plaques. Additionally, young apoE4-expressing mice had an elevated ratio of Aβ 40:42 in brain extracellular pools and a lower 40:42 ratio in CSF, suggesting that apoE4 results in altered clearance and transport of Aβ species within different brain compartments. These findings demonstrate that, once Aβ fibrillogenesis occurs, apoE4 favors the formation of CAA over parenchymal plaques and suggest that molecules or treatments that increase the ratio of Aβ 40:42 may favor the formation of CAA versus parenchymal plaques.

AB - Alzheimer's disease (AD) is characterized by the aggregation and deposition of the normally soluble amyloid-β (Aβ) peptide in the extracellular spaces of the brain as parenchymal plaques and in the walls of cerebral vessels as cerebral amyloid angiopathy (CAA). CAA is a common cause of brain hemorrhage and is found in most patients with AD. As in AD, the ε4 allele of the apolipoprotein E (apoE) gene (APOE) is a risk factor for CAA. To determine the effect of human apoE on CAA in vivo, we bred human APOE3 and APOE4 "knock-in" mice to a transgenic mouse model (Tg2576) that develops amyloid plaques as well as CAA. The expression of both human apoE isoforms resulted in a delay in Aβ deposition of several months relative to murine apoE. Tg2576 mice expressing the more fibrillogenic murine apoE develop parenchymal amyloid plaques and CAA by 9 months of age. At 15 months of age, the expression of human apoE4 led to substantial CAA with very few parenchymal plaques, whereas the expression of human apoE3 resulted in almost no CAA or parenchymal plaques. Additionally, young apoE4-expressing mice had an elevated ratio of Aβ 40:42 in brain extracellular pools and a lower 40:42 ratio in CSF, suggesting that apoE4 results in altered clearance and transport of Aβ species within different brain compartments. These findings demonstrate that, once Aβ fibrillogenesis occurs, apoE4 favors the formation of CAA over parenchymal plaques and suggest that molecules or treatments that increase the ratio of Aβ 40:42 may favor the formation of CAA versus parenchymal plaques.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Apolipoprotein E

KW - Cerebral amyloid angiopathy

KW - Ratio

KW - Transgenic models

UR - http://www.scopus.com/inward/record.url?scp=15244340676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15244340676&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.5170-04.2005

DO - 10.1523/JNEUROSCI.5170-04.2005

M3 - Article

C2 - 15772340

AN - SCOPUS:15244340676

VL - 25

SP - 2803

EP - 2810

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 11

ER -